Sunshine Biopharma (SBFM) Accumulated Expenses (2012 - 2021)

Sunshine Biopharma has reported Accumulated Expenses for 9 years, with the latest figure at $48287.0 in Q4 2021.

• For the quarter ending Q4 2021, Accumulated Expenses rose 213.71% year-over-year to $48287.0; the trailing twelve-month figure through Dec 2021 stood at $48287.0 (up 213.71% YoY), and the FY2021 full-year result was $48287.0, up 213.71% from the prior year.
• Accumulated Expenses for Q4 2021 stood at $48287.0, down from $84945.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $84945.0 in Q3 2021, with the low at $1171.0 in Q1 2017.
• Historically, Accumulated Expenses has averaged $29464.0 across 5 years, with a median of $28407.5 in 2018.
• Annual changes were most pronounced in 2018 — Accumulated Expenses surged 1772.25% — and 2020, when it retreated 29.85%.
• Sunshine Biopharma's Accumulated Expenses stood at $9215.0 in 2017, then gained by 0.82% to $9291.0 in 2018, then soared by 66.92% to $15509.0 in 2019, then slipped by 0.75% to $15392.0 in 2020, then soared by 213.71% to $48287.0 in 2021.
• The last three Accumulated Expenses figures came in at $48287.0 (Q4 2021), $84945.0 (Q3 2021), and $58712.0 (Q2 2021), per Business Quant data.